A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study
NCT ID: NCT00809510
Last Updated: 2011-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
63 participants
INTERVENTIONAL
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
NCT00555204
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease
NCT00069849
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
NCT01690195
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
NCT01676935
A Safety and Tolerability Study of ABT-126 in Elderly
NCT00867399
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ABT-089
20 mg ABT-089 taken once-daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-089
20 mg ABT-089 taken once-daily for 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject must remain on the same dose of AChEI that was used during the M06-876 study.
* The subject is in general good health, as judged by the investigator
Exclusion Criteria
* The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.
55 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Lenz
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 16543
Phoenix, Arizona, United States
Site Reference ID/Investigator# 16528
Sun City, Arizona, United States
Site Reference ID/Investigator# 16524
Fresno, California, United States
Site Reference ID/Investigator# 16520
San Diego, California, United States
Site Reference ID/Investigator# 16521
Santa Monica, California, United States
Site Reference ID/Investigator# 16533
Hamden, Connecticut, United States
Site Reference ID/Investigator# 16516
Brooksville, Florida, United States
Site Reference ID/Investigator# 16510
Deerfield Beach, Florida, United States
Site Reference ID/Investigator# 16508
Delray Beach, Florida, United States
Site Reference ID/Investigator# 16515
Miami, Florida, United States
Site Reference ID/Investigator# 16545
Palm Beach Gardens, Florida, United States
Site Reference ID/Investigator# 16541
Sunrise, Florida, United States
Site Reference ID/Investigator# 16542
Tampa, Florida, United States
Site Reference ID/Investigator# 16529
West Palm Beach, Florida, United States
Site Reference ID/Investigator# 16526
Indianapolis, Indiana, United States
Site Reference ID/Investigator# 16527
Eatontown, New Jersey, United States
Site Reference ID/Investigator# 16523
Ridgewood, New Jersey, United States
Site Reference ID/Investigator# 16532
New York, New York, United States
Site Reference ID/Investigator# 16519
Winston-Salem, North Carolina, United States
Site Reference ID/Investigator# 16525
Centerville, Ohio, United States
Site Reference ID/Investigator# 16507
Wichita Falls, Texas, United States
Site Reference ID/Investigator# 16509
Bennington, Vermont, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M10-745
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.